Royalty Pharma (RPRX) announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. Dr. Love serves as BIO’s Immediate Past Chair of its Board of Directors following a two-year term as Chairman. Previously, he served as President and CEO of Global Blood Therapeutics as well as a member of its board.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 9/17/2025
- Royalty Pharma Completes $2 Billion Senior Notes Offering
- Royalty Pharma: Strong Performance and Promising Outlook Justify Buy Rating
- Royalty Pharma ‘on track’ to deliver portfolio receipts of $4.7B by 2030
- Royalty Pharma’s Strategic Moves and Growth Prospects Justify Buy Rating